A hematologist-oncologist discusses the importance of biomarker testing in breast cancer, provides clinical insights on how to prioritize different testing assays, and outlines the roles of circulating tumor DNA and repeat testing. This is a modal window....
“The field of breast cancer research was arguably the first to realize that there are multiple cancer subtypes and that biomarker testing could help inform therapy,” said Pruitt. In the treatment of breast cancer, understanding various tumor biomarkers and pairing that understanding to help guide ...
How has the role of biomarker testing influenced emerging treatment considerations for patients with breast cancer? Biomarkers have [become] more available and there are plenty of targeted therapies now because of these additional biomarkers. We are looking at biomarkers that go beyond the estrogen rec...
Metastasis occurs when cells are shed from primary breast cancer tumor and establish a new tumor at a distant site. For early detection of the metastasis with MRI, the Lu Lab at Case Western University developed a probe that binds to fibrin-fibronectin protein complexes in high-risk tumors. Fi...
A review of medical records for almost 200 patients with breast cancer suggests that more selective use of biomarker testing for such patients has the potential to save millions of dollars in health care spending without compromising care, according to J
Biomarker testing in early-stage non-small cell lung cancer (NSCLC) and its importance in sequencing treatment was explored in a presentation by Christine M. Lovly, MD, PhD, at the 21st Annual Winter Lung Cancer Conference in Hollywood, Florida, sponsored by Physicians’ Education Resource, LLC...
An Analysis Of Biomarker Testing And Appropriate Treatment Among Women With Breast Cancer Using Oncology Emr DataMaternal MortalityHealth systemsSystematic ReviewResearch EvidenceBackground: The impact of efforts by healthcare organizations to enhance the use of evidence to improve organizational processes ...
(ctDNA) derived from tumor cells, show markedly elevated levels in cancer patients. Notably, ctDNA carries critical information on tumor-specific mutations, making it a valuable tool for non-invasive genetic testing. Exosomes, another type of nanoscale vesicle, are secreted in larger quantities by...
Olivotto IA, Truong PT, Speers CH, Bernstein V, Allan SJ, Kelly SJ et al (2004) Time to stop progesterone receptor testing in breast cancer management. J Clin Oncol 22:1769–1770 PubMedGoogle Scholar Allred DC (2008) Commentary: hormone receptor testing in breast cancer: a distress signal...
This patient group would benefit from tailored therapy that is based on biomarker testing. Although genetic alterations have been extensively characterized in breast cancer, we are just beginning to understand the changes in metabolism [2, 3] that occur downstream of genomic and proteomic alterations ...